



## **Mundipharma wins 1<sup>st</sup> ever PLG deal of the year award for acquisition of Cinfa Biotech**

- Win recognises the significance of the deal in enabling Mundipharma to further enhance Mundipharma's biosimilar platform offering

Cambridge. 26<sup>th</sup> February 2019 – The Mundipharma network of independent associated companies is delighted to announce its win at the 12th Annual Business Development Deal Awards which took place recently at the home of the Royal College of General Practitioners, 30 Euston Square in London.

The inaugural “PLG Deal of the Year”, sponsored by Thornton & Ross, recognised that the acquisition of Cinfa Biotech was a strategic fit, not only in terms of providing Mundipharma with additional medicines for its biosimilars portfolio, but in enabling the network to develop future biosimilars which will continue to afford healthcare systems further savings and wider access for patients.

Marco Cerato, head of BD and Strategic Partnerships commented: “I’m delighted that the PLG recognised the significance of our acquisition of Cinfa Biotech and the win is testament to the hard work of our business development team. Since bringing to market some of the first biosimilars in Europe, more patients than ever have benefitted from life changing biosimilar medicines, and we have saved hundreds of millions of Euros for Health Economies.

“With this acquisition, we have expanded our biosimilars footprint globally, and now have the capabilities, in-house, to develop future biosimilars. Since acquisition we have launched Pelmeg®, the fourth biosimilar in our portfolio, and we’re confident that our experience and capabilities launching biosimilars medicines will continue to deliver value for the healthcare systems we serve and our future biosimilars partners, with the ultimate goal of improving outcomes for patients.”

Business development leader, Jim MacDonald-Clink who was instrumental in the Cinfa Biotech acquisition came runner up in the PLG Executive of the year award.



-Ends-

**Notes to editors**

**About the Mundipharma network**

Mundipharma is a global network of privately-owned independent associated companies whose purpose is to move medicine forward.

With a high performing and learning organisation that strives for innovation and commercial excellence through partnerships, we successfully transformed and diversified our European portfolio of medicines to create value for patients, payers and wider healthcare systems across important therapeutic areas such as Diabetes, Respiratory, Oncology, Pain and Biosimilars.

For more information please visit: [www.mundipharma.com](http://www.mundipharma.com)

**For further information please contact:**

Alison Dyson

[Alison.dyson@mundipharma.com](mailto:Alison.dyson@mundipharma.com)

T: +44 (0)1223 397 346